Last reviewed · How we verify

ezetimibe with simvastatin

Organon and Co · Phase 3 active Small molecule

ezetimibe with simvastatin is a Cholesterol absorption inhibitor and statin Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Hypercholesterolemia, Mixed dyslipidemia.

Ezetimibe inhibits the absorption of cholesterol in the small intestine, while simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis.

Ezetimibe inhibits the absorption of cholesterol in the small intestine, while simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Used for Hypercholesterolemia, Mixed dyslipidemia.

At a glance

Generic nameezetimibe with simvastatin
SponsorOrganon and Co
Drug classCholesterol absorption inhibitor and statin
TargetNPC1L1 and HMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Ezetimibe works by binding to the Niemann-Pick C1-like 1 (NPC1L1) protein on the surface of intestinal cells, preventing the absorption of cholesterol from the diet. Simvastatin, on the other hand, inhibits HMG-CoA reductase, a key enzyme in the cholesterol synthesis pathway, which reduces the amount of cholesterol produced in the liver.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ezetimibe with simvastatin

What is ezetimibe with simvastatin?

ezetimibe with simvastatin is a Cholesterol absorption inhibitor and statin drug developed by Organon and Co, indicated for Hypercholesterolemia, Mixed dyslipidemia.

How does ezetimibe with simvastatin work?

Ezetimibe inhibits the absorption of cholesterol in the small intestine, while simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis.

What is ezetimibe with simvastatin used for?

ezetimibe with simvastatin is indicated for Hypercholesterolemia, Mixed dyslipidemia.

Who makes ezetimibe with simvastatin?

ezetimibe with simvastatin is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What drug class is ezetimibe with simvastatin in?

ezetimibe with simvastatin belongs to the Cholesterol absorption inhibitor and statin class. See all Cholesterol absorption inhibitor and statin drugs at /class/cholesterol-absorption-inhibitor-and-statin.

What development phase is ezetimibe with simvastatin in?

ezetimibe with simvastatin is in Phase 3.

What are the side effects of ezetimibe with simvastatin?

Common side effects of ezetimibe with simvastatin include Muscle pain, Liver enzyme elevations, Diarrhea.

What does ezetimibe with simvastatin target?

ezetimibe with simvastatin targets NPC1L1 and HMG-CoA reductase and is a Cholesterol absorption inhibitor and statin.

Related